NewsLeg ulcer treatment gets UK distributor

Leg ulcer treatment gets UK distributor

Leg Ulcers

Leg ulcer treatment gets UK distributorAccel-Heal® (Synapse Microcurrent Ltd), a compact and inexpensive electrical stimulation device, is to be distributed in the UK by Medicareplus International, part of the well-known Chemilines Group of companies who have been established for 28 years within the healthcare sector. Accel-Heal® can be used as an adjunct to compression bandaging in the management of venous leg ulcers. It has been shown to significantly accelerate healing and improve patient comfort, while saving money and delivering clinical efficacy.

ln 2009, independently conducted clinical trials on non-healing venous leg ulcers demonstrated that Accel-Heal® made significant reductions in ulcer size, exudate levels and pain in 95% of the trial patients, with 38% achieving full closure. Additionally, independent health economic analysis demonstrated a cost per QALY of minus £7,696 for Accel-Heal®.

Produced by class-leading ISO accredited healthcare company, Synapse Microcurrent Ltd, Accel-Heal® is now to be distributed in the UK by Medicareplus International, a company providing high-quality wound care consumables at competitive cost.

'Decision makers responsible for the providers of healthcare services are under increasing pressure to deliver cost-effective care whilst being mindful of not reducing quality,' said John Gildersleeve, CEO of Synapse. 'Because Accel-Heal® fulfills this objective so perfectly, we [Synapse] were not short of willing partners wanting to add our proprietary technology to their existing catalogue.

'Medicareplus International, with their enthusiastic approach, rapidly became the obvious and first choice to be our exclusive distributors for Accel-Heal® for the UK. lt's exciting to see a partner with recognised success in this sector, expand on Synapse's notable achievements to date. The fact that Medicareplus International have already committed orders further demonstrates their confidence in establishing Accel-Heal® as the "go to" solution for stimulating unresponsive wounds and consequently improving the quality of life for this group of long-suffering patients.'

Ravi Karia, Chemilines Group Managing Director expressed his excitement in entering this agreement with Synapse. 'We started our Medicareplus International division in 2008 with the express objective of providing quality products and delivering cost-effective solutions. I see Accel-Heal® as the ideal product to complement our expanding product portfolio, allowing us to provide huge savings within the healthcare sector.'

 

For further information about Accel-Heal®, including published papers, please go to: http://www.accelheal.com/

For further information about Medicareplus International, please go to: http://www.medicare-plus.com/